Rani Therapeutics Holdings, Inc.
RANI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RANI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RANI
Rani Therapeutics Holdings, Inc. is a clinical-stage biotech developing the RaniPill capsule, an oral biologic delivery platform, with collaborations including Chugai and ProGen, but faces significant financial uncertainty with a going concern risk and a need for substantial additional capital [sec_mda].
Key risk: Going concern risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$118.0M
Cash Runway
6.8 moLead Asset
rt-102 (Phase 1)
Next Catalyst
Phase3_Topline · Oct 1, 2032Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 4 clinical trials · 1 catalyst for Rani Therapeutics Holdings, Inc..
Similar companies
Rani Therapeutics Holdings, Inc. is a clinical-stage biotech developing the RaniPill capsule, an oral biologic delivery platform, with collaborations including Chugai and ProGen, but faces significant financial uncertainty with a going concern risk and a need for substantial additional capital [sec_mda].
- Rani Therapeutics is developing the RaniPill capsule, an oral delivery platform for biologics, with collaborations including Chugai Pharmaceutical Co. Ltd., ProGen Co. Ltd., and PegBio Co. Ltd. [sec_mda · as of 2026-08-13].
- As of March 31, 2026, the company had an accumulated deficit of $139.6 million and negative cash flows from operations of $6.5 million for the three months ended March 31, 2026 [sec_mda · as of 2026-05-15].
- Cash, cash equivalents, and marketable securities were $43.4 million as of March 31, 2026, expected to fund operations through at least twelve months from the issuance of that quarter's financial statements [sec_mda · as of 2026-05-15].
- The company anticipates needing to raise substantial additional capital, with the amount depending on factors including clinical trial progress, collaboration success, and regulatory outcomes [sec_mda · as of 2026-05-15].
- Latest reported financials as of 2026-06-30 show cash & equivalents of $5.1M, total revenue of $1.7M, net income of -$7.4M, and shareholders' equity of -$5.6M [sec].
What works
- Rani Therapeutics has established strategic partnerships with Chugai Pharmaceutical Co. Ltd., ProGen Co. Ltd., and PegBio Co. Ltd., which may provide milestone payments and development support [sec_mda · as of 2026-08-13].
- The RaniPill platform is designed to enable oral delivery of biologics, potentially addressing a large market need for non-injectable biologic therapies [sec_mda · as of 2026-08-13].
- The company expects its cash as of March 31, 2026 ($43.4M) to fund operations for at least twelve months, providing a runway into mid-2027 [sec_mda · as of 2026-05-15].
What to weigh
- Rani Therapeutics has an accumulated deficit of $139.6 million as of March 31, 2026, and has consistently generated negative cash flows from operations [sec_mda · as of 2026-05-15].
- The company faces substantial doubt about its ability to continue as a going concern and must raise additional capital, which may not be available on acceptable terms [sec_mda · as of 2026-05-15].
- Latest financials as of 2026-06-30 show negative shareholders' equity of -$5.6M and a cash position of only $5.1M, indicating a sharp decline in liquidity from the prior quarter [sec].
- The company's ability to advance product candidates depends on successful clinical trials, regulatory approvals, and continued collaboration support, all of which are uncertain [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Rani Therapeutics has collaborations with Chugai, ProGen, and PegBio.
“our ability to selectively enter into strategic partnerships and the expected potential benefits thereof, including our collaborations with Chugai Pharmaceutical Co. Ltd., ProGen Co. Ltd. and PegBio Co. Ltd.”
SEC MD&A · August 13, 2026
As of March 31, 2026, the company had an accumulated deficit of $139.6 million.
“March 31, 2026, the Company had an accumulated deficit of $ 139.6 million”
SEC MD&A · May 15, 2026
Cash, cash equivalents, and marketable securities were $43.4 million as of March 31, 2026.
“cash, cash equivalents and marketable securities of $ 43.4 million as of March 31, 2026”
SEC MD&A · May 15, 2026
The company expects to need substantial additional capital.
“We anticipate that we will need to raise substantial additional capital”
SEC MD&A · May 15, 2026
Catalyst timeline
- 2032-10-01 · Phase3_Topline — Phase 3 Topline: Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor — Topline results from a Phase 3 trial of elacestrant in node-positive, estrogen receptor-positive breast cancer; this is a long-dated catalyst.
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern; needs to raise capital [sec_mda · as of 2026-05-15].
- Cash runway uncertainty — Cash dropped from $43.4M (Mar 2026) to $5.1M (Jun 2026), indicating rapid burn [sec].
- Clinical and regulatory risk — Success depends on clinical trial outcomes, FDA acceptance, and partnership milestones [sec_mda · as of 2026-08-13].
- Accumulated losses — Accumulated deficit of $139.6M as of March 31, 2026, with no profitable operations [sec_mda · as of 2026-05-15].
What to watch
- Ability to secure additional financing or partnerships to extend cash runway beyond mid-2027 [sec_mda · as of 2026-05-15].
- Progress and data from clinical trials of RaniPill product candidates [sec_mda · as of 2026-08-13].
- Milestone achievements and updates from collaborations with Chugai, ProGen, and PegBio [sec_mda · as of 2026-08-13].
- Regulatory decisions from the FDA or other authorities regarding clinical trial data acceptance [sec_mda · as of 2026-05-15].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Rani Therapeutics Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Rani Therapeutics Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
6.8 months
D/E 0.33 · 0% dilution
Lead: Phase 1
4 candidates
1 upcoming, next in ~2224d
2 buys · 1 sell (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
71
Total value held
$25.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 9,245,134 | $6.8M |
| ra capital management, l.p. | 8,500,000 | $6.2M |
| samsara biocapital, llc | 8,500,000 | $6.2M |
| susquehanna international group, llp | 1,437,822 | $1.1M |
| geode capital management, llc | 903,298 | $664K |
| blackrock, inc. | 556,889 | $409K |
| nan fung group holdings ltd | 493,584 | $363K |
| 683 capital management, llc | 487,168 | $358K |
| vanguard fiduciary trust co | 455,050 | $334K |
| millennium management llc | 405,669 | $298K |
Showing top 10 of 71 institutional holders of Rani Therapeutics Holdings, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 10.4%
- Days to cover
- 7.4
- Shares short
- 10,113,183
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RANI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Rani Therapeutics Holdings, Inc.?
Rani Therapeutics Holdings, Inc. is a clinical-stage biotech developing the RaniPill capsule, an oral biologic delivery platform, with collaborations including Chugai and ProGen, but faces significant financial uncertainty with a going concern risk and a need for substantial additional capital [sec_mda].
What is Rani Therapeutics Holdings, Inc.'s lead drug candidate?
Rani Therapeutics Holdings, Inc.'s most advanced tracked candidate is rt-102 (Phase 1) for Osteoporosis.
What is Rani Therapeutics Holdings, Inc.'s next catalyst?
Rani Therapeutics Holdings, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor" — expected October 1, 2032.
Who is the CEO of Rani Therapeutics Holdings, Inc.?
Mr. Talat Imran is the chief executive officer of Rani Therapeutics Holdings, Inc. (RANI).
Where is Rani Therapeutics Holdings, Inc. headquartered?
Rani Therapeutics Holdings, Inc. (RANI) is headquartered in San Jose, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.